Neurocrine Biosciences 미래 성장

Future 기준 확인 5/6

Neurocrine Biosciences (는) 각각 연간 27.2% 및 12.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 25.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 21.3% 로 예상됩니다.

주요 정보

27.2%

수익 성장률

25.8%

EPS 성장률

Biotechs 수익 성장	28.8%
매출 성장률	12.2%
향후 자기자본 수익률	21.3%
애널리스트 커버리지	Good
마지막 업데이트	21 Feb 2025

최근 미래 성장 업데이트

Neurocrine Biosciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Feb 08

Recent updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Feb 21

Neurocrine Biosciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Feb 08

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 18

Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price

Dec 09

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

수익 및 매출 성장 예측

NasdaqGS:NBIX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	3,579	912	945	1,167	17
12/31/2026	3,143	665	751	889	19
12/31/2025	2,680	425	576	622	22
12/31/2024	2,355	341	557	595	N/A
9/30/2024	2,243	386	440	476	N/A
6/30/2024	2,120	339	495	530	N/A
3/31/2024	1,982	370	614	645	N/A
12/31/2023	1,887	250	362	390	N/A
9/30/2023	1,784	191	385	409	N/A
6/30/2023	1,673	176	281	296	N/A
3/31/2023	1,599	64	237	255	N/A
12/31/2022	1,489	155	323	339	N/A
9/30/2022	1,389	58	177	201	N/A
6/30/2022	1,297	12	133	164	N/A
3/31/2022	1,208	71	102	129	N/A
12/31/2021	1,134	90	233	257	N/A
9/30/2021	1,069	445	328	347	N/A
6/30/2021	1,032	365	251	265	N/A
3/31/2021	1,045	402	266	280	N/A
12/31/2020	1,046	407	218	229	N/A
9/30/2020	1,042	93	222	232	N/A
6/30/2020	1,006	205	337	350	N/A
3/31/2020	887	177	283	295	N/A
12/31/2019	788	37	132	147	N/A
9/30/2019	675	21	82	100	N/A
6/30/2019	605	18	44	71	N/A
3/31/2019	519	-39	0	27	N/A
12/31/2018	451	21	77	101	N/A
9/30/2018	414	10	N/A	91	N/A
6/30/2018	323	-52	N/A	13	N/A
3/31/2018	233	-106	N/A	-55	N/A
12/31/2017	162	-143	N/A	-94	N/A
9/30/2017	67	-194	N/A	-167	N/A
6/30/2017	6	-220	N/A	-188	N/A
3/31/2017	N/A	-200	N/A	-154	N/A
12/31/2016	15	-141	N/A	-106	N/A
9/30/2016	15	-126	N/A	-90	N/A
6/30/2016	15	-123	N/A	-77	N/A
3/31/2016	15	-107	N/A	-49	N/A
12/31/2015	20	-89	N/A	-38	N/A
9/30/2015	20	-79	N/A	-38	N/A
6/30/2015	20	-60	N/A	-32	N/A
3/31/2015	20	-50	N/A	-56	N/A
12/31/2014	N/A	-61	N/A	-47	N/A
9/30/2014	1	-52	N/A	-43	N/A
6/30/2014	1	-47	N/A	-41	N/A
3/31/2014	2	-46	N/A	-41	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NBIX 의 연간 예상 수익 증가율( 27.2% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: NBIX 의 연간 수익( 27.2% ) US 시장( 14.3% 보다 빠르게 성장할 것으로 예상됩니다. 14.3% 연간).

고성장 수익: NBIX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: NBIX 의 수익(연간 12.2% ) US 시장( 8.8% 보다 빠르게 성장할 것으로 예상됩니다. 8.8% 연간).

고성장 수익: NBIX 의 수익(연간 12.2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NBIX 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 21.3 %)

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/02/22 17:23
장 마감 주가	2025/02/21 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Neurocrine Biosciences, Inc. 43 애널리스트 중 22 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Martha Freitag	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Neurocrine Biosciences 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Neurocrine Biosciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025

Consensus EPS estimates fall by 12%

Price target increased by 7.0% to US$172

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Consensus EPS estimates fall by 12%

Recent updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $500 million worth of its shares.

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2024 earnings: EPS misses analyst expectations

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. to Report Q4, 2024 Results on Feb 06, 2025

Director exercised options and sold US$17m worth of stock

Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia

Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price

Chief Medical Officer exercised options to buy US$903k worth of stock.

Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares.

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

The Play On Neurocrine Biosciences

Chief Corporate Affairs Officer notifies of intention to sell stock

Chief Corporate Affairs Officer notifies of intention to sell stock

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Investor sentiment deteriorates as stock falls 18%

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Price target increased by 7.0% to US$172

Independent Chairman of the Board recently sold US$2.1m worth of stock

Independent Director exercised options and sold US$1.2m worth of stock

Chief Human Resources Officer exercised options and sold US$1.2m worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock